China National Medicines Corporation Ltd. (SHA:600511)
30.32
+0.50 (1.68%)
Apr 1, 2025, 2:45 PM CST
SHA:600511 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
Operating Revenue | 50,597 | 49,592 | 45,436 | 46,442 | 40,336 | Upgrade
|
Other Revenue | - | 103.99 | 62.95 | 26.26 | 43.04 | Upgrade
|
Revenue | 50,597 | 49,696 | 45,499 | 46,469 | 40,379 | Upgrade
|
Revenue Growth (YoY) | 1.81% | 9.22% | -2.09% | 15.08% | -9.55% | Upgrade
|
Cost of Revenue | 47,002 | 45,704 | 41,681 | 42,848 | 37,242 | Upgrade
|
Gross Profit | 3,595 | 3,992 | 3,817 | 3,621 | 3,136 | Upgrade
|
Selling, General & Admin | 1,267 | 1,430 | 1,392 | 1,355 | 1,404 | Upgrade
|
Research & Development | 73.71 | 71.2 | 67 | 55.75 | 51.87 | Upgrade
|
Other Operating Expenses | 117.34 | 109.69 | 46.91 | 120.86 | 105.54 | Upgrade
|
Operating Expenses | 1,458 | 1,618 | 1,498 | 1,566 | 1,571 | Upgrade
|
Operating Income | 2,138 | 2,374 | 2,319 | 2,055 | 1,566 | Upgrade
|
Interest Expense | - | -31.57 | -26.88 | -43.71 | -56.81 | Upgrade
|
Interest & Investment Income | 514.17 | 525.32 | 362.42 | 354.09 | 279.16 | Upgrade
|
Currency Exchange Gain (Loss) | - | 0.55 | -1.65 | 2.71 | 1.57 | Upgrade
|
Other Non Operating Income (Expenses) | 21.4 | -10.47 | -43.29 | -18 | 2.24 | Upgrade
|
EBT Excluding Unusual Items | 2,673 | 2,858 | 2,609 | 2,350 | 1,792 | Upgrade
|
Gain (Loss) on Sale of Investments | -18.2 | 10.82 | - | - | - | Upgrade
|
Gain (Loss) on Sale of Assets | -0.19 | 0.08 | 1.68 | -0.07 | 0.07 | Upgrade
|
Asset Writedown | -1.07 | - | - | - | - | Upgrade
|
Other Unusual Items | - | 62.44 | 76.9 | 95.08 | 125.4 | Upgrade
|
Pretax Income | 2,654 | 2,931 | 2,688 | 2,445 | 1,917 | Upgrade
|
Income Tax Expense | 523.83 | 596.42 | 559.18 | 516.3 | 408.09 | Upgrade
|
Earnings From Continuing Operations | 2,130 | 2,334 | 2,129 | 1,929 | 1,509 | Upgrade
|
Minority Interest in Earnings | -129.65 | -188.47 | -164.65 | -174.42 | -126.56 | Upgrade
|
Net Income | 2,000 | 2,146 | 1,964 | 1,754 | 1,383 | Upgrade
|
Net Income to Common | 2,000 | 2,146 | 1,964 | 1,754 | 1,383 | Upgrade
|
Net Income Growth | -6.80% | 9.26% | 11.97% | 26.86% | -13.79% | Upgrade
|
Shares Outstanding (Basic) | 755 | 754 | 755 | 755 | 754 | Upgrade
|
Shares Outstanding (Diluted) | 755 | 754 | 755 | 755 | 754 | Upgrade
|
Shares Change (YoY) | 0.00% | -0.00% | - | 0.00% | -0.98% | Upgrade
|
EPS (Basic) | 2.65 | 2.84 | 2.60 | 2.32 | 1.83 | Upgrade
|
EPS (Diluted) | 2.65 | 2.84 | 2.60 | 2.32 | 1.83 | Upgrade
|
EPS Growth | -6.80% | 9.27% | 11.97% | 26.86% | -12.94% | Upgrade
|
Free Cash Flow | 1,528 | 2,582 | 2,265 | 1,862 | 1,233 | Upgrade
|
Free Cash Flow Per Share | 2.03 | 3.42 | 3.00 | 2.47 | 1.63 | Upgrade
|
Dividend Per Share | - | 0.854 | 0.782 | 0.700 | 0.550 | Upgrade
|
Dividend Growth | - | 9.21% | 11.71% | 27.27% | -13.79% | Upgrade
|
Gross Margin | 7.11% | 8.03% | 8.39% | 7.79% | 7.77% | Upgrade
|
Operating Margin | 4.23% | 4.78% | 5.10% | 4.42% | 3.88% | Upgrade
|
Profit Margin | 3.95% | 4.32% | 4.32% | 3.77% | 3.42% | Upgrade
|
Free Cash Flow Margin | 3.02% | 5.20% | 4.98% | 4.01% | 3.05% | Upgrade
|
EBITDA | 2,256 | 2,480 | 2,423 | 2,155 | 1,669 | Upgrade
|
EBITDA Margin | 4.46% | 4.99% | 5.32% | 4.64% | 4.13% | Upgrade
|
D&A For EBITDA | 118.63 | 106.15 | 103.86 | 100.1 | 103.46 | Upgrade
|
EBIT | 2,138 | 2,374 | 2,319 | 2,055 | 1,566 | Upgrade
|
EBIT Margin | 4.23% | 4.78% | 5.10% | 4.42% | 3.88% | Upgrade
|
Effective Tax Rate | 19.74% | 20.35% | 20.80% | 21.12% | 21.28% | Upgrade
|
Revenue as Reported | - | 49,696 | 45,499 | 46,469 | 40,379 | Upgrade
|
Advertising Expenses | - | 6.7 | 3.25 | 2.25 | 3.2 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.